Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas

Reports of Practical Oncology and Radiotherapy

Volumn 20, Issue 3, 2015, Pages 231-238

  Conde Moreno, Antonio José ^a   García Gómez, Raquel ^a   Albert Antequera, María ^a   Almendros Blanco, Piedad ^a   De Las Peñas Bataller, Ramón ^a   González Vidal, Verónica ^a   López Torrecilla, José Luis ^a   Ferrer Albiach, Carlos ^a  

^a HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

Author keywords

Bevacizumab; Fractionated stereotactic radiotherapy; High grade glioma; Rescue treatment

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FRACTIONATED STEREOTACTIC RADIOTHERAPY; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 84927784075     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2015.01.004     Document Type: Article

References (25)

1. Mirimanoff R.O. High-grade gliomas: reality and hopes. Chin J Cancer 2014, 33(January (1)):1-3.
2. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolamide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Cabrera A.R., Cuneo K.C., Desjardins A., et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys 2013, 86(5):873-879.
4. Shapiro L.Q., Beal K., Goenka A., et al. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 2013, 85(3):636-642.
5. Cuneo K.C., Vredenburgh J.J., Sampson J.H., et al. Safety and efficacy of steretotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2012, 82(5):2018-2024.
6. Combs S.E., Edler L., Rausch R., Welzel T., Wick W., Debus J. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol 2013, 52:147-152.
7. Park J.K., Hodges T., Arko L., et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010, 28:3838-3843.
8. Mayer R., Sminia P. Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 2008, 70(5):1350-1360.
9. Paulino A.C., Mai W.Y., Chintagumpala M., Taher A., Teh B.S. Radiation-induced malignant gliomas: is there a role for reirradiation?. Int J Radiat Oncol Biol Phys 2008, 71(5):1381-1387.
10. ® brachytherapy. Int J Radiat Oncol Biol Phys 2005, 62(4):1133-1139.
11. Chao S.T., Ahluwalia M.S., Barnett G.H., et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int J Radiat Oncol Biol Phys 2013, 87(3):449-457.
12. Levin V.A1, Bidaut L., Hou P., et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011, 79(5):1487-1495.
13. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740.
14. Chinot O.L., de La Motte Rouge T., Moore N., et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011, 28(4):334-340.
15. Soffietti R., Trevisan E., Rudà R. What have we learned from trials on antiangiogenic agents in glioblastoma?. Expert Rev Neurother 2014, 14(January (1)):1-3.
16. Kreisl T.N., Zhang W., Odia Y., et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol 2011, 13(October (10)):1143-1150.
17. Khasraw M., Ameratunga M., Gommes C. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. Expert Opin Biol Ther 2014, 14(5):729-740.
18. Gutin P.H., Iwamoto F.M., Beal K., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009, 75(1):156-163.
19. Niyazi M., Ganswindt U., Schwarz S.B., et al. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 2012, 82(1):67-76.
20. Torcuator R.G., Thind R., Patel M., et al. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol 2010, 97(May (3)):401-407.
21. Comas S., Villà S., Etxaniz O., et al. Patterns of relapse in glioblastoma after neoadjuvancy and radiation therapy. Rep Pract Oncol Radiother 2013, 18:S195.
22. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
23. Krex D., Klink B., Hartmann C., et al. Long-term survival with glioblastoma multiforme. Brain 2007, 130(10):2596-2606.
24. Würth R., Barbieri F., Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int 2014, 2014:126586. [Epub Jan 2, 2014]. 10.1155/2014/126586.
25. Gorlia T., Stupp R., Brandes A.A., et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 2012, 48(8):1176-1184.